Skip to main content

Home/ Cancer/ Group items tagged 2009 PCA

Rss Feed Group items tagged

Matti Narkia

The cancer 'TRAP' - 2 views

  •  
    "Worcester, MA - Current research suggests that TNF-receptor associated protein-1 (TRAP-1) may prevent cancer cell death. The related report by Leav et al, "Cytoprotective Mitochondrial Chaperone TRAP-1 as a Novel Molecular Target in Localized and Metastatic Prostate Cancer," appears in the January 2010 issue of the American Journal of Pathology.

    Prostate cancer cells are often resistant to cell death. Researchers led by Dr. Dario C. Altieri of the University of Massachusetts Medical School, therefore, explored the role of TRAP-1, a protein thought to regulate cell death, in prostate cancer survival. TRAP-1 was highly expressed in both high-grade human prostate cancer lesions and mouse models of prostate cancer, but not in benign or normal prostate tissue. In addition, TRAP-1 overexpression in non-cancer prostate cells inhibited cell death, whereas TRAP-1-deficient prostate cancer cells had enhanced levels of cell death. Moreover, treatment with Gamitrinib, which inhibits TRAP-1, resulted in prostate cancer cell death, but not death of non-cancerous prostate cells. Therefore, targeting TRAP-1 via Gamitrinib treatment may be a viable therapeutic strategy for patients with advanced prostate cancer."
Matti Narkia

Briefing: Cannabis compounds fight prostate cancer - health - 19 August 2009 - New Scie... - 2 views

  •  
    "Compounds similar to those found in cannabis have been shown to stop prostate cancer cells from multiplying. Two cannabinoid compounds, JWH-015 and MET, stopped prostate tumour growth in human prostate cells in Petri dishes and also in mice with the disease. They halted the cell-division cycle and killed the cancer cells, and had the greatest effect on aggressive prostate cancer cell types, which do not respond to hormone treatments.

    Some 192,000 men in the US alone are diagnosed with prostate cancer each year, and researchers Inés Díaz-Laviada Marturet at the University of Alcalá, Spain, and her colleagues say the results could offer hope to those affected. But before you go looking for a dealer, New Scientist answers a few questions"
Matti Narkia

The Relevance of Vitamin D Receptor (VDR) Gene Polymorphisms for Cancer: A Review of th... - 0 views

  •  
    The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature.
    Köstner K, Denzer N, Müller CS, Klein R, Tilgen W, Reichrath J.
    Anticancer Res. 2009 Sep;29(9):3511-36. Review.
    PMID: 19667145

    CONCLUSION: Significant associations with VDR polymorphisms have been reported in cancer of the breast (Fok1, Bsm1, Taq1, Apa1, poly (A)), prostate (Fok1, Bsm1, Taq1, poly (A)), skin (Fok1, Bsm1, A-1210), colorectum (Fok1, Bsm1), ovary (Fok1, Apa1) and bladder (Fok1), and in renal cell carcinoma (Taq1, Apa1). However, conflicting data have been reported for most malignancies. After careful evaluation of the actual literature, it can be summarized that data indicating an association of VDR polymorphisms and cancer risk are strongest for breast cancer (Bsm1, Fok1), prostate cancer (Fok1) and malignant melanoma (MM) (Fok1). Data indicating an association of VDR polymorphisms and cancer prognosis are strongest for prostate cancer (Fok1), breast cancer (Bsm1, Taq1), MM (Bsm1) and renal cell carcinoma (Taq1).
Matti Narkia

Association between serum 25(OH)D and death from prostate cancer - British Journal of C... - 0 views

  •  
    Association between serum 25(OH)D and death from prostate cancer.
    Tretli S, Hernes E, Berg JP, Hestvik UE, Robsahm TE.
    Br J Cancer. 2009 Feb 10;100(3):450-4. Epub 2009 Jan 20.
    PMID: 19156140
    doi:10.1038/sj.bjc.6604865

    The serum level of 25(OH)D may be involved in disease progression and is a potential marker of prognosis in patients with prostate cancer.
Matti Narkia

Mayo researchers: Dramatic outcomes in prostate cancer study - 0 views

  •  
    ROCHESTER, Minn. -- Two Mayo Clinic patients whose prostate cancer had been considered inoperable are now cancer free thanks in part to an experimental drug therapy that was used in combination with standardized hormone treatment and radiation therapy. The men were participating in a clinical trial of an immunotherapeutic agent called MDX-010 or ipilimumab. In these two cases, physicians say the approach initiated the death of a majority of cancer cells and caused the tumors to shrink dramatically, allowing surgery. In both cases, the aggressive tumors had grown well beyond the prostate into the
Matti Narkia

Green tea 'slows prostate cancer' - BBC NEWS | Health - 0 views

  •  
    A chemical found in green tea appears to slow the progression of prostate cancer, a study has suggested.
    Green tea has been linked to a positive effect on a wide range of conditions, including heart disease, cancer and Alzheimer's disease.
Matti Narkia

Carbohydrate restriction may slow prostate tumor growth - eurekalert.org - 0 views

  •  
    DURHAM, N.C. -- Restricting carbohydrates, regardless of weight loss, appears to slow the growth of prostate tumors, according to an animal study being published this week by researchers in the Duke Prostate Center.

    "Previous work here and elsewhere has shown that a diet light in carbohydrates could slow tumor growth, but the animals in those studies also lost weight, and because we know that weight loss can restrict the amount of energy feeding tumors, we weren't able to tell just how big an impact the pure carbohydrate restriction was having, until now," said Stephen Freedland, M.D., a urologist in the Duke Prostate Center and lead investigator on this study.

    The researchers believe that insulin and insulin-like growth factor contribute to the growth and proliferation of prostate cancer, and that a diet devoid of carbohydrates lowers serum insulin levels in the bodies of the mice, thereby slowing tumor growth, Freedland said.
Matti Narkia

Serum Vitamin D and Risk of Prostate Cancer in a Case-Control Analysis Nested Within th... - 0 views

  •  
    Serum Vitamin D and Risk of Prostate Cancer in a Case-Control Analysis Nested Within the European Prospective Investigation into Cancer and Nutrition (EPIC).
    Travis RC, Crowe FL, Allen NE, Appleby PN, Roddam AW, Tjønneland A, Olsen A, Linseisen J, Kaaks R, Boeing H, Kröger J, Trichopoulou A, Dilis V, Trichopoulos D, Vineis P, Palli D, Tumino R, Sieri S, Bueno-de-Mesquita HB, van Duijnhoven FJ, Chirlaque MD, Barricarte A, Larrañaga N, González CA, Argüelles MV, Sánchez MJ, Stattin P, Hallmans G, Khaw KT, Bingham S, Rinaldi S, Slimani N, Jenab M, Riboli E, Key TJ.
    Am J Epidemiol. 2009 Apr 9. [Epub ahead of print]
    PMID: 19359375
    doi:10.1093/aje/kwp022
Matti Narkia

Vitamin D and Intervention Trials in Prostate Cancer: From Theory to Therapy - 0 views

  •  
    Vitamin D and intervention trials in prostate cancer: from theory to therapy.
    Schwartz GG.
    Ann Epidemiol. 2009 Feb;19(2):96-102. Epub 2008 Jul 10.
    PMID: 18619854
    doi:10.1016/j.annepidem.2008.03.007

    This suggests that whereas vitamin D (e.g., cholecalciferol) might prevent prostate cancer, existing prostate tumors likely would require treatment with 1,25(OH)(2)D and/or its analogs. The major obstacle to the use of 1,25(OH)(2)D in patients therapeutically is the risk of hypercalcemia. Several maneuvers to reduce this risk, including pulse dosing and the use of less calcemic 1,25(OH)(2)D analogs, have been explored in Phase I-III clinical trials. Once merely a promise, vitamin D-based therapies for prostate cancer may soon be medical practice.
Matti Narkia

CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependen... - 0 views

  •  
    CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer.
    Ang JE, Olmos D, de Bono JS.
    Br J Cancer. 2009 Mar 10;100(5):671-5. Epub 2009 Feb 17.
    PMID: 19223900
    doi:10.1038/sj.bjc.6604904
Matti Narkia

Sham vs. Wham: The Health Insider: Omega 3 In the News Again - Lower Advanced Prostate ... - 0 views

  •  
    new (March 24th) report in Clinical Cancer Research, a journal of the American Association for Cancer Research, shows that Omega-3 fatty acids appear protective against advanced prostate cancer.

    Dr. John S. Witte, Ph.D., professor of epidemiology and biostatistics at the University of California San Francisco, says that previous research has shown protection against prostate cancer, but that this is one of the first studies to show protection against advanced prostate cancer.
Matti Narkia

Dietary Omega-3 Fatty Acids, Cyclooxygenase-2 Genetic Variation, and Aggressive Prostat... - 0 views

  •  
    Dietary Omega-3 Fatty Acids, Cyclooxygenase-2 Genetic Variation, and Aggressive Prostate Cancer Risk.
    Fradet V, Cheng I, Casey G, Witte JS.
    Clin Cancer Res. 2009 Mar 24. [Epub ahead of print]
    PMID: 19318492
    DOI: 10.1158/1078-0432.CCR-08-2503
Matti Narkia

Folic Acid Supplements Linked To Higher Risk Of Prostate Cancer, Study Shows - 0 views

  •  
    ScienceDaily (Mar. 10, 2009) - A study led by researchers at the University of Southern California (USC) found that men who took a daily folic acid supplement of 1 mg daily had more than twice the risk of prostate cancer compared with men who took a placebo.
Matti Narkia

Differential effects of selenium on benign and malignant prostate epithelial cells: sti... - 0 views

  •  
    Differential effects of selenium on benign and malignant prostate epithelial cells: stimulation of LNCaP cell growth by noncytotoxic, low selenite concentrations.
    Kandaş NO, Randolph C, Bosland MC.
    Nutr Cancer. 2009;61(2):251-64.
    PMID: 19235042
Matti Narkia

Older Men Urged to Consider a Drug to Prevent Prostate Cancer - NYTimes.com - 0 views

  •  
    For the first time, medical groups have issued guidelines that say healthy older men should consider taking a drug that may reduce their risk of developing prostate cancer, even if they're just among the worried well who go in for regular screenings.\n\nThe drug, finasteride, is already used to treat male pattern baldness and to shrink enlarged prostates. The new guidelines suggest that patients who are already taking finasteride for those conditions or who go for regular prostate cancer screening tests should discuss long-term treatment with the drug with their doctors.
Matti Narkia

New Lab Evidence Suggests Preventive Effect Of Herbal Supplement In Prostate Cancer - 0 views

  •  
    When these cell cultures were treated with red clover isoflavones, the androgenic effects of DHEA were reversed.
    "Something is happening in the prostate tissue microenvironment that is illustrating a potential cancer prevention effect from this supplement," said Arnold.
    Red clover isoflavones may modify androgenic effects in the prostate but much more work in the laboratory and clinic is needed to validate these effects.
1 - 16 of 16
Showing 20 items per page